Exagen (XGN) to Release Quarterly Earnings on Tuesday

Exagen (NASDAQ:XGN) is expected to release its earnings data before the market opens on Tuesday, March 11th. Analysts expect Exagen to post earnings of ($0.27) per share and revenue of $13.85 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Exagen Price Performance

XGN stock opened at $3.06 on Tuesday. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54. Exagen has a 12 month low of $1.30 and a 12 month high of $6.22. The firm has a market cap of $53.97 million, a P/E ratio of -3.26 and a beta of 1.41. The company’s 50-day moving average price is $3.98 and its two-hundred day moving average price is $3.57.

Analyst Upgrades and Downgrades

Several research firms have commented on XGN. William Blair reissued an “outperform” rating on shares of Exagen in a report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $8.00 target price on shares of Exagen in a report on Monday, January 13th. Finally, Canaccord Genuity Group raised their target price on shares of Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, January 3rd.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).